Annals of Hematology

, Volume 94, Issue 2, pp 283–287 | Cite as

Sustained remission of blastic plasmacytoid dendritic cell neoplasm after unrelated allogeneic stem cell transplantation—a single center experience

  • Thomas Heinicke
  • Heiko Hütten
  • Thomas Kalinski
  • Ingolf Franke
  • Bernd Bonnekoh
  • Thomas Fischer
Original Article


Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematodermic neoplasm which typically presents with skin infiltrates with or without lymphadenopathy and bone marrow involvement. No standard of care exists for this aggressive disease and prognosis is particularly poor. Here, we present our experience with nine BPDCN patients diagnosed at our institution between 2005 and 2012. BPDCN patients were identified in the databases at the Department of Hematology and Oncology, the Department of Dermatology, and the Institute of Pathology at the Otto-von-Guericke-University Magdeburg. There were six male and three female patients with a median age at diagnosis of 66 years. Sites involved were skin (five cases), lymph nodes (five cases), and bone marrow (five cases). Treatments varied from single agent chemotherapy to polychemotherapy and allogeneic stem cell transplantation for consolidation. The three patients that were treated with acute leukemia-type induction therapy followed by allogeneic stem cell transplantation (one after standard conditioning and two after reduced intensity conditioning using fludarabine in combination with thiotepa) achieved sustained remissions and are alive with a follow-up of 8, 35, and 41 months. In contrast, median survival in the less intensively treated patients was only 9.5 (range 1 to 29) months.


Blastic plasmacytoid dendritic cell neoplasm Hematopoietic stem cell transplantation Thiotepa 


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Facchetti FJD, Petrella T (2008) Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow SH et al (eds) WHO classification of tumors of haematopoietic and lymphoid tissues. IARC, Lyon, FranceGoogle Scholar
  2. 2.
    Dalle S et al (2010) Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 162(1):74–79PubMedCrossRefGoogle Scholar
  3. 3.
    Julia F et al (2013) Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 169(3):579–586PubMedCrossRefGoogle Scholar
  4. 4.
    Pagano L et al (2013) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 98(2):239–246PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    An HJ et al (2013) Blastic plasmacytoid dendritic cell neoplasm: a single-center experience. Ann Hematol 92(3):351–356PubMedCrossRefGoogle Scholar
  6. 6.
    Petrella T et al (2005) Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 123(5):662–675PubMedCrossRefGoogle Scholar
  7. 7.
    Garnache-Ottou F, Feuillard J, Saas P (2007) Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? Br J Haematol 136(4):539–548PubMedCrossRefGoogle Scholar
  8. 8.
    Garnache-Ottou F et al (2009) Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 145(5):624–636PubMedCrossRefGoogle Scholar
  9. 9.
    Reimer P et al (2003) What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant 32(7):637–646PubMedCrossRefGoogle Scholar
  10. 10.
    Ham JC et al (2012) Allogeneic stem-cell transplantation for blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol 30(8):e102–e103PubMedCrossRefGoogle Scholar
  11. 11.
    Kaloyannidis P et al (2010) GVL effect in plasmacytoid DC leukemia/lymphoma. Bone Marrow Transplant 45(5):961–962PubMedCrossRefGoogle Scholar
  12. 12.
    Unteregger M et al (2013) Unrelated SCT induces long-term remission in patients with blastic plasmacytoid dendritic cell neoplasm. Bone Marrow Transplant 48(6):799–802PubMedCrossRefGoogle Scholar
  13. 13.
    Grullich C et al (2008) A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. Bone Marrow Transplant 41(10):845–850PubMedCrossRefGoogle Scholar
  14. 14.
    Roos-Weil D et al (2013) Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 121(3):440–446PubMedCrossRefGoogle Scholar
  15. 15.
    Dietrich S et al (2011) Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant 17(8):1250–1254PubMedCrossRefGoogle Scholar
  16. 16.
    Kharfan-Dabaja MA et al (2013) Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant 19(7):1006–1012PubMedCrossRefGoogle Scholar
  17. 17.
    Goren Sahin D et al (2013) Blastic plasmacytoid dendritic cell leukemia successfully treated by autologous hematopoietic stem cell transplantation to a remission of 48-month duration. Case Rep Hematol 2013:471628PubMedCentralPubMedGoogle Scholar
  18. 18.
    Horn TD et al (1989) Observations and proposed mechanism of N, N', N''-triethylenethiophosphoramide (thiotepa)-induced hyperpigmentation. Arch Dermatol 125(4):524–527PubMedCrossRefGoogle Scholar
  19. 19.
    Rosman IS et al (2008) Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol 58(4):575–578PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Thomas Heinicke
    • 1
  • Heiko Hütten
    • 1
  • Thomas Kalinski
    • 2
  • Ingolf Franke
    • 3
  • Bernd Bonnekoh
    • 3
  • Thomas Fischer
    • 1
  1. 1.Department of Hematology and Oncology, Medical CenterOtto-von-Guericke-University MagdeburgMagdeburgGermany
  2. 2.Institute of Pathology, Medical CenterOtto-von-Guericke-University MagdeburgMagdeburgGermany
  3. 3.Department of Dermatology, Medical CenterOtto-von-Guericke-University MagdeburgMagdeburgGermany

Personalised recommendations